Butterfly Network (BFLY)
(Delayed Data from NYSE)
$1.72 USD
+0.04 (2.38%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $1.71 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.72 USD
+0.04 (2.38%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $1.71 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Zacks News
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVEO Pharmaceuticals (AVEO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
New Strong Sell Stocks for April 25th
by Zacks Equity Research
BALY, BFLY, and DNN have been added to the Zacks Rank #5 (Strong Sell) List on April 25, 2022
New Strong Sell Stocks for April 20th
by Zacks Equity Research
BBBY, BALY, and BFLY have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2022.
New Strong Sell Stocks for March 18th
by Zacks Equity Research
BFLY, DAN, and ECPG have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2022
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
What Makes Butterfly Network, Inc. (BFLY) a New Buy Stock
by Zacks Equity Research
Butterfly Network, Inc. (BFLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.